PT  - JOURNAL ARTICLE
AU  - Akbar, Md Navid
AU  - Ruf, Sebastian F.
AU  - Singh, Ashutosh
AU  - Faghihpirayesh, Razieh
AU  - Garner, Rachael
AU  - Bennett, Alexis
AU  - Alba, Celina
AU  - La Rocca, Marianna
AU  - Imbiriba, Tales
AU  - Erdoğmuş, Deniz
AU  - Duncan, Dominique
TI  - Advancing Post-Traumatic Seizure Classification and Biomarker Identification: Information Decomposition Based Multimodal Fusion and Explainable Machine Learning with Missing Neuroimaging Data
AID  - 10.1101/2022.10.22.22281402
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2022.10.22.22281402
4099  - http://medrxiv.org/content/early/2024/03/18/2022.10.22.22281402.short
4100  - http://medrxiv.org/content/early/2024/03/18/2022.10.22.22281402.full
AB  - A late post-traumatic seizure (LPTS), a consequence of traumatic brain injury (TBI), can potentially evolve into a lifelong condition known as post-traumatic epilepsy (PTE). Presently, the mechanism that triggers epileptogenesis in TBI patients remains elusive, inspiring the epilepsy community to devise ways to predict which TBI patients will develop PTE and to identify potential biomarkers. In response to this need, our study collected comprehensive, longitudinal multimodal data from 48 TBI patients across multiple participating institutions. A supervised binary classification task was created, contrasting data from LPTS patients with those without LPTS. To accommodate missing modalities in some subjects, we took a two-pronged approach. Firstly, we extended a graphical model-based Bayesian estimator to directly classify subjects with incomplete modality. Secondly, we explored conventional imputation techniques. The imputed multimodal information was then combined, following several fusion and dimensionality reduction techniques found in the literature, and subsequently fitted to a kernel- or a tree-based classifier. For this fusion, we proposed two new algorithms: recursive elimination of correlated components (RECC) that filters information based on the correlation between the already selected features, and information decomposition and selective fusion (IDSF), which effectively recombines information from decomposed multimodal features. Our cross-validation findings showed that the proposed IDSF algorithm delivers superior performance based on the area under the curve (AUC) score. Ultimately, after rigorous statistical comparisons and interpretable machine learning examination using Shapley values of the most frequently selected features, we recommend the two following magnetic resonance imaging (MRI) abnormalities as potential biomarkers: the left anterior limb of internal capsule in diffusion MRI (dMRI), and the right middle temporal gyrus in functional MRI (fMRI).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) under award number R01NS111744.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the University of California, Los Angeles (UCLA) Institutional Review Board (IRB# 16-001 576) and the local review boards at each EpiBioS4Rx Study Group institution. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed in this study is subject to the following licenses/restrictions: access to data must be requested and approved by the EpiBioS4Rx steering committee. Requests to access these datasets should be directed to epibiossteeringcommittee{at}loni.usc.edu. https://epibios.loni.usc.edu/